Chinook Therapeutics Inc. completed the acquisition of Aduro Biotech, Inc. in a reverse merger transaction.
Upon closing, Eric Dobmeier will be the President and Chief Executive Officer of the combined company. Senior leadership of the combined company will also include Tom Frohlich as Chief Business Officer, Alan Glicklich, as Chief Medical Officer, Andrew King, as head of renal discovery and translational medicine and Renata Oballa, as Vice President of chemistry. In connection with the merger, Stephen T. Isaacs, Chairman, President and Chief Executive Officer of Aduro, will be stepping down. The Board of Directors of the combined company will be comprised of seven directors namely Eric Dobmeier, President and Chief Executive Officer of Chinook Therapeutics, Jerel Davis, Managing Director at Versant Ventures, Srini Akkaraju, Managing General Partner at Samsara BioCapital, William M. Greenman, President and Chief Executive Officer of Cerus Corporation and Ross Haghighat, Founder, Chairman and Managing Partner of Triton Systems, Inc. along with two additional independent directors. The combined company will be headquartered out of Chinook's existing facilities in Vancouver, BC and Seattle, Washington.
The transaction is subject to the satisfaction or waiver of customary closing conditions, including the receipt of the required approval of the shareholders of Aduro and Chinook. The transaction is also subject to closing of the sale and issuance of the Notes pursuant to the Note Purchase Agreement, the continuous listing of the shares of the new combined company, the shares of the combined company to be issued being approved for listing on Nasdaq as of the closing, the Registration Statement having become effective, lock up agreement between the parties, execution of the support agreement where the parties have agreed to vote all of their shares of capital stock in favor of the transaction, Aduro's net cash as of closing being equal to or greater than $135 million and Chinook's cash and cash equivalents as of closing being equal to or greater than $5 million. The transaction is also subject to any waiting period applicable to the consummation under the HSR Act shall have expired or been terminated. The transaction has been unanimously approved by the Board of Directors of both Aduro and Chinook. The Board of Aduro and Chinook recommend the shareholders to approve the transaction. As of October 1, 2020, the transaction was approved by shareholders of Aduro Biotech, Inc. Following stockholder approval, the company announced a one-for-five reverse stock split. The Aduro's common stock will begin trading on a split-adjusted basis on The Nasdaq Global Select Market effective with the open of the market on Friday, October 2, 2020. The transaction is expected to be completed in the second half of 2020. The transaction is expected to be completed in fourth quarter of 2020. As of October 1, 2020, the transaction is expected to close on or around October 5, 2020.
SVB Leerink is acting as financial advisor and will receive an aggregate fee of $2.0 million, $1.0 million of which became payable upon the rendering its opinion and the remainder of which is payable contingent upon consummation of the transaction and Luke Bergstrom, Alan Mendelson, James Metz, Maj Vaseghi, Grace Lee, Ben Haas, Joshua Holian, Patrick English, Robert Blamires, Christopher Hazuka and Kathleen Wells of Latham & Watkins LLP acted as legal counsels to Aduro Biotech, Inc. Andrew Weisenfeld and Samuel Ball-Brau of MTS Health Partners is acting as financial advisor and Effie Toshav, Ethan Skerry, Robert Freedman, Amanda Rose, Matthew Cantor, Stefano Quintini, Antonia Sequeira, Amy Klann and William Skinner of Fenwick & West LLP are acting as legal counsels to Chinook. MacKenzie Partners, Inc. acted as information agent and will receive a fees of approximately $20,000, plus reimbursement. Fried Frank acted as counsel to SVB Leerink LLC.
Chinook Therapeutics Inc. completed the acquisition of Aduro Biotech, Inc. (NasdaqGS:ADRO) in a reverse merger transaction on October 5, 2020. Upon closing of the transaction, Chinook Therapeutics was cancelled and exchanged for 0.292188 shares of Common Stock of the Issuer for no consideration, which resulted in its shareholders Versant Venture Capital VII, L.P., Versant Voyageurs I Parallel, L.P. and Versant Voyageurs I, L.P. receiving approximately 7.8 million shares. Upon close of the transaction, prior Chinook stockholders collectively own approximately 39.5% of the combined company, prior Aduro stockholders collectively own approximately 39.9% of the combined company and investors in the Chinook private placement financing collectively own approximately 20.6% of the combined company. Chinook Therapeutics also completed the $115 million private placement financing in connection with the transaction. The combined company will commence trading on October 6, 2020 on the Nasdaq. Effective as of the closing of the merger, the Board of Directors of Chinook will be comprised of seven directors: Eric Dobmeier, President and Chief Executive Officer of Chinook Therapeutics; Jerel Davis, Managing Director at Versant Ventures; Srini Akkaraju, Managing General Partner at Samsara BioCapital; William M. Greenman; Ross Haghighat; Michelle Griffin; and Dolca Thomas.